- Home
- INCR vs ABOS Comparison
INCR vs ABOS Comparison
Compare INCR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- ABOS
- Stock Information
- Founded
- INCR 1994
- ABOS 1996
- Country
- INCR Israel
- ABOS United States
- Employees
- INCR N/A
- ABOS N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- INCR Health Care
- ABOS Health Care
- Exchange
- INCR Nasdaq
- ABOS Nasdaq
- Market Cap
- INCR 76.7M
- ABOS 76.9M
- IPO Year
- INCR N/A
- ABOS 2021
- Fundamental
- Price
- INCR $1.60
- ABOS $1.22
- Analyst Decision
- INCR
- ABOS Strong Buy
- Analyst Count
- INCR 0
- ABOS 3
- Target Price
- INCR N/A
- ABOS $9.33
- AVG Volume (30 Days)
- INCR 29.6K
- ABOS 217.9K
- Earning Date
- INCR 03-25-2025
- ABOS 03-25-2025
- Dividend Yield
- INCR N/A
- ABOS N/A
- EPS Growth
- INCR N/A
- ABOS N/A
- EPS
- INCR N/A
- ABOS N/A
- Revenue
- INCR $72,420,918.00
- ABOS N/A
- Revenue This Year
- INCR N/A
- ABOS N/A
- Revenue Next Year
- INCR $39.30
- ABOS N/A
- P/E Ratio
- INCR N/A
- ABOS N/A
- Revenue Growth
- INCR N/A
- ABOS N/A
- 52 Week Low
- INCR $1.17
- ABOS $1.10
- 52 Week High
- INCR $3.72
- ABOS $4.43
- Technical
- Relative Strength Index (RSI)
- INCR 46.96
- ABOS 42.29
- Support Level
- INCR $1.54
- ABOS $1.19
- Resistance Level
- INCR $1.62
- ABOS $1.31
- Average True Range (ATR)
- INCR 0.05
- ABOS 0.08
- MACD
- INCR -0.00
- ABOS 0.01
- Stochastic Oscillator
- INCR 31.45
- ABOS 54.38
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.